1-4 of 4
Philippe Solal-Céligny, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies, MD, Francesco Merli, Biljana Mihaljevik, Noppadol Siritanaratkul, MD, Philippe Solal-Céligny, MD, Axel Boehnke, Claude Berge, Christine McIntyre, Martin Barrett, PhD, David Macdonald, MD, FRCPC
Journal: Blood
Blood (2012) 120 (21): 1629.
https://doi.org/10.1182/blood.V120.21.1629.1629
Published: 2012
Journal Articles

High Response Rate and Low Toxicity of Rituximab, Vinorelbine, Ifosfamide, Mitoxantrone and Prednisone Combination for the Treatment of Diffuse Large B Cell Lymphoma In First Relapse: Early Results of the R-NIMP GOELAMS Study.

Emmanuel Gyan, MD, PhD, Delphine Senecal, MD, Philippe Quittet, MD, Charles Foussard, MD, Anne Banos, MD, Steven Le Gouill, MD, PhD, Charles Dauriac, MD, Julie Léger, Jean Fontan, MD, Diane Damotte, MD, Hervé Maisonneuve, MD, Magda Alexis, MD, Francois Dreyfus, MD, PhD, Stéphane Courby, MD, Jean-Louis Dutel, MD, Olivier Tournilhac, MD, PhD, Kamel Laribi, MD, Philippe Solal-Céligny, MD, Annick Le Pourhiet-Le Mevel, MD, Nina Arakelyan, MD, Henry Jardel, MD, Remy Gressin, MD
Journal: Blood
Blood (2010) 116 (21): 2796.
https://doi.org/10.1182/blood.V116.21.2796.2796
Published: 2010
Journal Articles

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)

Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, PhD, Catherine Thieblemont, MD, PhD, Philippe Solal-Céligny, MD, Thierry Lamy, MD, PhD, Herve Tilly, MD, Pierre Feugier, MD, PhD, Steven Le Gouill, MD, Emmanuel Gyan, MD, PhD, Reda Bouabdallah, MD, Michael Wenger, MD, Joe Birkett, PhD, Guillaume Cartron, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2868.
https://doi.org/10.1182/blood.V116.21.2868.2868
Published: 2010
Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD
Journal: Blood
Blood (2008) 112 (11): lba-1.
https://doi.org/10.1182/blood.V112.11.lba-1.lba-1
Published: 2008